4.9 Hemolytic Disease of th Fetus and Newborn Flashcards
All of the following are reasons for a positive DAT on cord blood cells of a newborn except:
A. High concentrations of Wharton jelly on cord blood cells
B. Immune anti-A from an O mother on the cells of an A baby
C. Immune anti-D from an Rh negative mother on the cells of an Rh-positive baby
D. Immune anti-K from a K-negative mother on the cells of a K-negative baby
D. Immune anti-K from a K-negative mother on the cells of a K-negative baby
A fetal screen yielded negative results on a mother who is O negative and infant who is O positive. What course of action should be taken?
A. Perform a Kleihauer-Betke test
B. Issue one full dose of RhIg
C. Perform a DAT on the infant
D. Perform an antibody screen on the mother
B. Issue one full dose of RhIg
What should be done when a woman who is 24 weeks pregnant has a positive antibody screen?
A. Perform an antibody identification panel; titer, if necessary
B. No need to do anything until 30 weeks’ gestation
C. Administer RhIg
D. Adsorb the antibody onto antigen-positive cells
A. Perform an antibody identification panel; titer, if necessary
All of the following are interventions for fetal distress caused by maternal antibodies attacking fetal cells except:
A. Intrauterine transfusion
B. Plasmapheresis on the mother
C. Transfusion of antigen-positive cells to the mother
D. Middle cerebral artery peak systolic velocity (MCA-PSV)
C. Transfusion of antigen-positive cells to the mother
Cord blood cells are washed six times with saline, and the DAT result and negative control are still positive. What should be done next?
A. Obtain a heelstick sample
B. Record the DAT result as positive
C. Obtain another cord blood sample
D. Perform elution on the cord blood cells
A. Obtain a heelstick sample
What can be done if HDFN is caused by maternal anti-K?
A. Give Kell immune globulin
B. Monitor the mother’s antibody level
C. Prevent formation of K-positive cells in the fetus
D. Not a problem; anti-K is not known to cause HDFN
B. Monitor the mother’s antibody level
Anti-D is the only antibody for which prevention of HDFN is possible. If a pregnant woman develops anti-K, she will be monitored to determine if the antibody level and signs of fetal. distress necessitate clinical intervention.
Should an O-negative mother receive RhIg if a positive DAT on the newborn is caused by immune anti-A?
A. No, the mother is not a candidate for RhIg because of the positive DAT result
B. Yes, if the baby’s type is Rh negative
C. Yes, if the baby’s type is Rh positive
D. No, the baby’s problem is unrelated to Rh blood group antibodies
C. Yes, if the baby’s type is Rh positive
RhIg is immune anti-D and is given to Rh negative mothers who give birth to Rh-positive babies and who do not have anti-D already formed from previous pregnancies or transfusion.
Should an A-negative woman who has just had a miscarriage receive RhIg?
A. Yes, but only if she does not have evidence of active anti-D
B. No, the type of the baby is unknown
C. Yes, but only a minidose regardless of trimester
D. No, RhIg is given to women at full-term pregnancies only
A. Yes, but only if she does not have evidence of active anti-D
When the fetus is Rh positive or the Rh status of the fetus is unknown, termination of a pregnancy from any cause presents a situation in which an Rh-negative patient should receive RhIg. A minidose is used if the pregnancy is terminated in the first trimester.
SITUATION: The automated blood bank analyzer reports a type of O negative on a woman who is 6 weeks pregnant with vaginal bleeding. The woman tells the emergency department physician she is O positive and presents a blood donor card. The MLS performs a test for weak D and observes a 1+ reaction in the AHG phase. The Kleihauer-Betke test result is negative. Is this woman a candidate for RhIg?
A. Molecular testing is indicated to ascertain the type of weak D
B. Yes, she is Rh positive
C. No, there is no evidence of a fetal bleed
D. Yes, based on the automated typing results
A. Molecular testing is indicated to ascertain the type of weak D
The negative Kleihauer-Betke test result confirms that the positive reaction of the woman’s RBCs with anti-D at the IAT phase is not the result of fetal-maternal bleeding. The woman is weak D positive and, therefore, requires molecular testing to discern if she is a candidate for RhIg. Weak D types 1, 2, 3, and 4 do not make anti-D and do not require RhIg prophylaxis.
Which of the following patients would be a candidate for RhIg?
A. B-positive mother; B-negative baby; first pregnancy; no anti-D in mother
B. O-negative mother; A-positive baby; second pregnancy; no anti-D in mother
C. A-negative mother; O-negative baby; fourth pregnancy; anti-D in mother
D. AB-negative mother; B-positive baby; second pregnancy; anti-D in mother
B. O-negative mother; A-positive baby; second pregnancy; no anti-D in mother
An O-negative mother who gives birth to an A-positive baby and has no anti-D formed from a previous pregnancy would be a candidate for RhIg. A mother who already has active anti-D or a mother who gives birth to an Rh-negative baby is not a candidate for RhIg. Anti-D formation via active immunization typically has a titer greater than 4, compared with passive administration of anti-D, which has a titer less than 4.
The Kleihauer-Betke acid elution test identifies 40 fetal cells in 2,000 maternal RBCs. How many full doses of RhIg are indicated?
A. 1
B. 2
C. 3
D. 4
D. 4
To calculate the number of vials of RhIg to infuse, divide 40 by 2,000, and multiply by 5,000. This gives the estimated total blood volume of the mother in mililiters. Divide this number by 30 to obtain the number of doses. When the number to the right of the decimal point is less than 5, round down, and add one does of RhIg. Conversely, when the number to the right of the decimal point is 5 or greater, round up, and add one dose of RhIg. In this example, the number of doses is 3.3. Rounding down and adding one vial gives an answer of four vials.
Kernicterus is caused by the effects of:
A. Anemia
B. Unconjugated bilirubin
C. Antibody specificity
D. Antibody titer
B. Unconjugated bilirubin
Anti-E is detected in the serum of a woman in her first trimester of pregnancy. The first titer for anti-E is 32. Two weeks later, the antibody titer is 64 and then 128 after another 2 weeks. Clinically, there are beginning signs of fetal distress. What may be done?
A. Induce labor for early delivery
B. Perform plasmapheresis to remove anti-E from the mother
C. Administer RhIg to the mother
D. Perform an intrauterine transfusion using E-negative cells
B. Perform plasmapheresis to remove anti-E from the mother
What testing is done for exchange transfusion when the mother’s serum contains an alloantibody?
A. Crossmatching and antibody screen
B. ABO, Rh, antibody screen, and crossmatching
C. ABO, Rh, antibody screen
D. ABO and Rh only
B. ABO, Rh, antibody screen, and crossmatching
ABO (forward) Rh are required. An antibody screen using either the neonatal serum or maternal serum is required. Crossmatching is necessary as long as maternal antibody persists in the infant’s blood.
Which blood type may be transfused to an AB-positive baby who has HDFN caused by anti-D?
A. AB negative, CMV negative, Hgb S negative; irradiated or O negative, CMV negative, Hgb S negative
B. AB positive, CMV negative; irradiated or O positive, CMV negative
C. AB negative only
D. O negative only
A. AB negative, CMV negative, Hgb S negative; irradiated or O negative, CMV negative, Hgb S negative